A randomised prospective study of transurethral electro vaporisation versus laser ablation of the prostate in men with benign prostatic hypertrophy

1999 ◽  
Vol 9 (2) ◽  
pp. 173
Author(s):  
Nic Bryan
Keyword(s):  
Laser Ablation ◽  
Prospective Study ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy

Nd:YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy

1992 ◽  
Vol 12 (2) ◽  
pp. 121-124 ◽  
Author(s):  
Anthony J. Costello ◽  
Douglas E. Johnson ◽  
Damien M. Bolton
Keyword(s):  
Laser Ablation ◽  
Nd:Yag Laser ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy

Laser Ablation of the Prostate in Patients with Benign Prostatic Hypertrophy

1992 ◽  
Vol 69 (6) ◽  
pp. 603-608 ◽  
Author(s):  
A. J. COSTELLO ◽  
W. G. BOWSHER ◽  
D. M. BOLTON ◽  
K. G. BRASLIS ◽  
J. BURT
Keyword(s):  
Laser Ablation ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy

Laser treatment of benign prostatic hypertrophy

1996 ◽  
Vol 63 (1) ◽  
pp. 77-80
Author(s):  
S. Guazzieri ◽  
W. Cecchetti ◽  
M. Meneguolo ◽  
G. D'incà ◽  
R. Bertoldin
Keyword(s):  
Laser Treatment ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Laser Source ◽  
Experimental Procedure ◽  
The Usa ◽  
Side Emission ◽  
Pace Maker ◽  
Stable Laser ◽  
Good Flow

— Laser treatment of benign prostatic hypertrophy (BPH) has gradually become more widespread over the last few years. In the USA it is considered an alternative to endoscopic resection as far as insurance payments are concerned. Different methods are used but the most common and suitable one for urologists is the removal and coagulation of the prostatic tissue under visual control (VLAP or ELAP). The Authors report their personal experience in this type of treatment where good results are due to: 1) combination of a powerful, stable laser source 2) durable side-emission contact fibre 3) laser resector, which also in the absence of epicystostomy maintains a good flow during the operation. However, “laser resection” should still be considered an experimental procedure to be used for randomised protocols or on selected patients (high risk of bleeding, Jehovah's witnesses, carriers of pace-maker, etc.).

SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHY

1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire
Keyword(s):  
Plasma Levels ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Control Subjects ◽  
Peripheral Plasma ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
And Control

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.

Sign in / Sign up

Export Citation Format

Share Document